Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KURN.SW
- Price
- 17.36
- Stock movement down
- -0.70 (-3.88%)
- Company name
- Kuros Biosciences AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Medical Devices
- Market cap
- 652.27M
- Ent value
- 655.12M
- Price/Sales
- 8.61
- Price/Book
- 10.84
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.95%
- 1 year return
- 190.30%
- 3 year return
- 109.06%
- 5 year return
- 57.90%
- 10 year return
- -15.92%
Last updated: 2025-04-05
DIVIDENDS
KURN.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8.61 |
| Price to Book | 10.84 |
| EV to Sales | 8.65 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 37.57M |
| EPS (TTM) | -0.49 |
| FCF per share (TTM) | -0.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 75.76M |
| Gross profit (TTM) | 62.92M |
| Operating income (TTM) | -11.64M |
| Net income (TTM) | -18.28M |
| EPS (TTM) | -0.49 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 83.05% |
| Operating margin (TTM) | -15.37% |
| Profit margin (TTM) | -24.12% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.28M |
| Net receivables | 10.98M |
| Total current assets | 33.24M |
| Goodwill | 24.74M |
| Intangible assets | 16.17M |
| Property, plant and equipment | 0.00 |
| Total assets | 77.30M |
| Accounts payable | 2.83M |
| Short/Current long term debt | 5.57M |
| Total current liabilities | 12.16M |
| Total liabilities | 17.13M |
| Shareholder's equity | 60.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.21M |
| Capital expenditures (TTM) | 1.06M |
| Free cash flow (TTM) | -11.27M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -30.37% |
| Return on Assets | -23.64% |
| Return on Invested Capital | -30.07% |
| Cash Return on Invested Capital | -18.54% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 17.42 |
| Daily high | 18.42 |
| Daily low | 17.00 |
| Daily Volume | 377K |
| All-time high | 11956.37 |
| 1y analyst estimate | 20.05 |
| Beta | 0.76 |
| EPS (TTM) | -0.49 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 17 Apr 2025 |
Downside potential
Loading...
Downside potential data
| KURN.SW | S&P500 | |
| Current price drop from All-time high | -99.85% | -17.56% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 26 Apr 2023 | 9 Mar 2009 |
| Avg drop from high | -80.33% | -11.07% |
| Avg time to new high | 104 days | 12 days |
| Max time to new high | 4500 days | 1805 days |
COMPANY DETAILS
Marketcap
652.27M
Marketcap category
Small-cap
Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Employees
106
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8...
March 11, 2025
Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, ...
January 7, 2025
Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company's acceleration beyond the spine market Strategic expansion opens new addres...
November 19, 2024
Financial Highlights Direct MagnetOsTM sales rose by 149% to CHF 50.6 million in the first nine months of 2024, from CHF 20.4 million in the same period in 2023 Total Kuros Medical Devices segment sal...
October 10, 2024
Financial Highlights Direct MagnetOs™ sales increased by 159% to CHF 31.6 million from CHF 12.2 million in H1 2023; this corresponds to a sequential increase of 62% or CHF 12.1 million over H2 2023 To...
August 8, 2024
ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details ...
June 25, 2024
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 20...
April 24, 2024
ZURICH, SWITZERLAND / ACCESSWIRE / April 17, 2024 / Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting...
April 17, 2024